Immunovant Revenue and Competitors
Estimated Revenue & Valuation
- Immunovant's estimated annual revenue is currently $16.9M per year.
- Immunovant's estimated revenue per employee is $68,125
- Immunovant's total funding is $200M.
- Immunovant's current valuation is $903.9M. (January 2022)
Employee Data
- Immunovant has 248 Employees.
- Immunovant grew their employee count by 35% last year.
Immunovant Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Immunovant?
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Our investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection. We have initiated Phase 2 studies in two target indications: myasthenia gravis (MG) and Gravesᅢᄁ¬ツᆲ¬トᄁ ophthalmopathy (GO). We anticipate that we will submit an IND in one additional indication, warm autoimmune hemolytic anemia (WAIHA), in the second half of 2019. We plan to continue expanding our pipeline with innovative therapies that could transform the lives of patients living with autoimmune diseases. *Please note that all applications should be placed through our official career site: https://lnkd.in/gyVgXhZ We will never email you to ask for personal information such as SSN or banking information nor would we ever ask a candidate for payment of any kind as part of the hiring or onboarding process.
keywords:N/A$200M
Total Funding
248
Number of Employees
$16.9M
Revenue (est)
35%
Employee Growth %
$903.9M
Valuation
N/A
Accelerator
Immunovant's People
Name | Title | Email/Phone |
---|---|---|
1 | VP, Program and Alliance Management | Reveal Email/Phone |
2 | Associate Director, Clinical Laboratories | Reveal Email/Phone |
3 | Senior Clinical Trial Manager | Reveal Email/Phone |
4 | Senior Manager, Site Relationship Management | Reveal Email/Phone |
5 | Clinical Trial Manager | Reveal Email/Phone |
6 | Director, Head Patient Recruitment | Reveal Email/Phone |
7 | Director, Analytical Sciences & Technology | Reveal Email/Phone |
8 | VP, Biostatistics and Programming | Reveal Email/Phone |
9 | Director, Technical Accounting and SEC Reporting | Reveal Email/Phone |
10 | Sr. Director, Clinical Operations | Reveal Email/Phone |
Immunovant News
Immunovant has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, La Jolla Pharmaceutical has...
Immunovant, Inc. (NASDAQ:IMVT) Given Average Recommendation of Hold by Analysts. Posted by admin on Apr 22nd, 2022.
Immunovant, Inc. (NASDAQ:IMVT) CEO Peter Salzmann Sells 19,227 Shares. Posted by admin on Apr 14th, 2022. Share on Twitter Share on Facebook Share on...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $35M | 248 | 12% | $205.7M |
#2 | $68.2M | 248 | -12% | N/A |
#3 | $40.9M | 248 | 8% | N/A |
#4 | $15M | 248 | 28% | N/A |
#5 | $37.3M | 248 | 0% | $114.6M |
Immunovant Executives
Name | Title |
---|---|
Pete Salzmann | Chief Executive Officer |
Mark Levine | Chief Legal Officer and Corporate Secretary |
Leigh-Ann Martin | Executive Assistant, Office of the CEO |
Beverly Paperiello | Senior Vice President of Program Strategy & Chief Medical Officer |
Rita Jain | Chief Medical Officer |
Pete Salzmann | CEO |
Julia Butchko | Chief Development and Technology Officer |
Bill Macias | Chief Medical Officer |
Paula Wong | Executive Assistant to Chief of Development & Technology Officer |
Renee Barnett | CFO |
Jean Wilson | Chief Legal Officer and Corporate Secretary |
Yan Zheng | VP, Biostatistics and Programming |
Jim Haney | Vice President Finance |
Jyotin Vyas | Vice President, Global Program and Alliance Management |
Maria Alba | Vice President Clinical Research |
Ron Bates | VP, CMC Process Development and Technical Operations |
Jody Roth | Vice President |
Lauren Schrier | Vice President, Marketing |
Bagyashree Sundaram | Vice President, Head of Regulatory Affairs |
Tracy Newbold | Vice President, Clinical Operations |
Thomas Hardy | Vice President, Drug Safety and Pharmacovigilance |
Kiran Singh | VP Cmc Drug product & Supply chain |
Beverly Paperiello | Senior Vice President of Program Strategy & Chief Medical Officer |
Rod Saponjic | VP Clinical Operations |
Ronald Bates | Vice President of CMC Process Development |
Andy Deig | Vice President of Financial Planning |
Lesa Valentine | Vice President, Quality |
Daniel Isaacman | VP, Clinical Development |
Chedva Sister | VP, SEC Reporting, Technical Accounting & Tax |
Chedvi Levin-Sister | VP, SEC Reporting, Technical Accounting and Tax |
Jody Roth | Vice President of Global Regulatory Affairs |
Yan Zheng | Vice President Of Biostatistics and Programming |
Joanne Lancaster | Vice President, Program and Alliance Management |